The FDA has approved GE Healthcare’s Q.Clear, a technology that GE says improves accuracy when assessing a patient’s response to treatment.
The U.S. Food and Drug Administration (FDA) has approved Q.Clear, a technology by GE Healthcare that improves accuracy and quality in PET/CT imaging.
Q.Clear is an innovative tool that can provide up to two times improvement in both quantitative accuracy and image quality, according to a release. While technology in PET image reconstruction has improved over the last decade and provides better image quality, reduced acquisition time and lower injected dose, current technologies may force a compromise between image quality and quantitation. GE claims that Q.Clear technology shows the advantage of full convergence PET imaging without compromising quantitation and image quality.
Q.Clear provides clinicians with the ability to detect smaller lesions and determine earlier whether a patient is responding to current treatment. When combined with GE Healthcare’s Q.Suite, Q.Clear enables clinicians to assess treatment response more accurately, according to the release.
“We know that approximately 70 percent of cancer patients don’t always respond to their initial course of treatment,” Steve Gray, president and CEO of GE Healthcare MICT, said in a release. “If we can give clinicians an accurate, reliable and faster tool to confirm that a change in treatment is needed, the patient will benefit greatly. For example, PET/CT can help clinicians determine whether chemotherapy is working in fewer cycles, saving patients unnecessary procedures.”
Q.Clear is not yet available for countries that require CE marking.
Multicenter CT Study Shows Benefits of Emerging Diagnostic Model for Clear Cell Renal Cell Carcinoma
May 15th 2024Combining clinical and CT features, adjunctive use of a classification and regression tree (CART) diagnostic model demonstrated AUCs for detecting clear cell renal cell carcinoma (ccRCC) that were 15 to 22 percent higher than unassisted radiologist assessments.
What a New Meta-Analysis Reveals About Fractional Flow Reserve Assessment with Computed Tomography
May 13th 2024While acknowledging variable accuracy overall with CT-derived fractional flow reserve (FFR-CT) values, researchers found that the accuracy rate increased to 90 percent for FFR-CT values greater > 0.90 and < 0.49.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Finds High Concordance Between AI and Radiologists for Cervical Spine Fractures on CT
May 6th 2024Researchers found a 98.3 percent concordance between attending radiology reports and AI assessments for possible cervical spine fractures on CT, according to new research presented at the 2024 ARRS Annual Meeting.
FDA Clears AI-Powered Qualitative Perfusion Mapping for Cone-Beam CT
May 6th 2024Reportedly validated in more than 10 clinical trials, the AngioFlow perfusion imaging software enables timely identification of brain regions with cerebral blood flow reduction and those with significant hypoperfusion.